Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Simulect (Basiliximab) - Important Safety Information from Novartis Ireland as approved by the Health Products Regulatory Authority
Notice type:
3rd Party Publications
Date:
09/09/2014
Background Information Or Related Documents:
Important Safety Information communication from Novartis Ireland on Simulect (Basiliximab) - warning against off-label use in cardiac transplantation.
Important Safety Information - Simulect (Basiliximab)
« Back
Date Printed: 29/03/2024